Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTREPId
NCT04025372Phase 2Active, not recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Jun 2020
- Primary completion
- Oct 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide in prostate cancer (PCa), sponsored by Brigham and Women's Hospital. Started Jun 2020; status: active, not recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04025372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04025372.